Infleqtion Shares Fall Below IPO Price in Post-Merger Trading

BenzingaBenzinga
|||1 min read
Key Takeaway

Infleqtion shares fell 7% below their IPO opening price after completing a SPAC merger, now trading at 52-week lows amid broader market weakness and typical post-merger price discovery.

Infleqtion Shares Fall Below IPO Price in Post-Merger Trading

Infleqtion Inc. (NYSE:INFQ) has experienced a sharp reversal following its public market entry through a merger with Churchill Capital Corp X, with shares declining to $12.36, representing a 7% loss from their opening level. The quantum technology company completed the transaction last week after raising approximately $550 million in capital, with initial investor enthusiasm reflected in a 15% single-day surge that has since dissipated.

The pullback comes as typical for newly public companies undergoing price discovery in secondary market trading, a period characterized by volatile investor positioning and valuation reassessment. The decline has coincided with broader weakness across equity markets, with major indices experiencing sell-offs that have pressured technology and emerging sector equities more broadly.

Shares are now trading at 52-week lows as the market adjusts to the company's public valuation following its merger completion. The pullback illustrates the distinction between initial public enthusiasm and sustained trading interest, a common pattern in special purpose acquisition company (SPAC) mergers.

Source: Benzinga

Back to newsPublished Feb 25

Related Coverage

Benzinga

Relativity Acquisition Shareholders OK SPAC Merger with Stem Cell Pioneer Instinct Bio

Relativity Acquisition shareholders approve SPAC merger with stem cell company Instinct Bio Technical, enabling Nasdaq listing under $BIOT and $BIOTW expected within weeks.

ACQC
GlobeNewswire Inc.

Relativity Acquisition Corp. Shareholders Greenlight SPAC Merger with Instinct Bio

Relativity Acquisition Corp. shareholders approved merger with stem cell firm Instinct Bio Technical Company Inc. Combined entity to trade on Nasdaq as $BIOT and $BIOTW.

ACQC
GlobeNewswire Inc.

Corcept Therapeutics Faces Class Action Over FDA Rejection; Stock Crashed 50%

Corcept Therapeutics faces securities fraud lawsuit after FDA rejected relacorilant application. Stock plummeted 50.4% following December rejection. Investor deadline April 21, 2026.

CORT
Investing.com

D-Wave's 44% Plunge Masks Quantum Leap: Growth Story vs. Valuation Reality

D-Wave ($QBTS) fell 44% in 2026 despite strong bookings exceeding 2025 totals and $30M in major deals. Analysts see 132% upside, but 237x sales valuation remains extreme.

QBTS
GlobeNewswire Inc.

OneMain Holdings Faces Multi-State Securities Probe Over Alleged Lending Fraud

Pomerantz Law Firm investigates $OMF following multi-state lawsuit alleging deceptive lending practices. Stock tumbles 5.38% on fraud allegations.

OMF
GlobeNewswire Inc.

Boston Scientific Faces Securities Fraud Lawsuit Over Overstated EP Growth Claims

Boston Scientific faces class action lawsuit alleging material misstatements about electrophysiology growth. Stock fell 17.6% after disclosing slower market growth and competitive pressures.

BSX